证券代码：301228 证券简称：实朴检测 公告编号：2025-060 实朴检测技术（上海）股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 实朴检测技术（上海）股份有限公司（以下简称"公司" 、"本公司"） 于 2025 年 4 月 22 日召开第二届董事会第十八次会议，于 2025 年 5 月 16 日召开 公司 2024 年年度股东大会，审议通过了《关于为全资子公司提供担保的议案》， 同意公司为全资子公司上海实朴智创科技有限公司（以下简称"实朴智创"）向 银行、金融机构等申请融资（包括但不限于办理人民币或外币流动资金贷款、项 目贷款、承兑汇票、信用证、保函、票据贴现、保理、出口押汇以及外汇远期结 售汇等相关业务）时提供担保，担保额度不超过人民币 1.5 亿元，担保期限 12 个 月，自公司 2024 年年度股东大会审议通过之日起算。 具体内容详见公司于 2025 年 4 月 24 日及 2025 年 5 月 16 日在巨潮资讯网 （www.cninfo.com.cn）上披露的《关于为全资子 ...

国泰海通证券股份有限公司 关于实朴检测技术（上海）股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐人名称：国泰海通证券股份有限公司 | 被保荐公司简称：实朴检测 | | --- | --- | | 保荐代表人姓名：曾军 | 联系电话：021-23180000 | | 保荐代表人姓名：石冰洁 | 联系电话：021-23180000 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0次 | | 2.督导公司建立健全并有效执行规章制度的 | | | 情况 | | | （1）是否督导公司建立健全规章制度（包括 但不限于防止关联方占用公司资源的制度、 | 是 | | 募集资金管理制度、内控制度、内部审计制度、 | | | 关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月一次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | ...

Core Insights - A total of 135 stocks reported their latest shareholder numbers as of August 31, with 78 stocks showing a decline compared to the previous period [1][3] - The stocks with the largest decrease in shareholder numbers include Boyuan Co., Yalian Machinery, and Shibu Detection, with declines exceeding 10% [3] Group 1: Shareholder Data - Boyuan Co. had the largest decline in shareholder numbers, down 26.59% to 9,715 shareholders, while its stock price increased by 63.29% since the concentration of shares began [3] - Yalian Machinery's shareholder count decreased by 25.51% to 7,337, with a stock price increase of 5.99% during the same period [3] - A total of 11 stocks experienced a decline in shareholder numbers exceeding 10% [3] Group 2: Market Performance - The average increase for concentrated stocks from August 21 was 0.23%, with 26% of these stocks outperforming the Shanghai Composite Index [2] - The highest stock price increase since August 11 was for Yidong Electronics, which rose by 41.06% [2] - The sectors with the most concentrated stocks include machinery equipment, pharmaceuticals, and automotive, with 13, 6, and 5 stocks respectively [3]

Group 1 - The core point of the article indicates that Shibu Testing has seen a significant decrease in the number of shareholders, with a reduction of 1,313 shareholders to a total of 6,471, representing a 16.87% decrease compared to the previous period [2] - As of the latest data, Shibu Testing's closing price is 27.50 yuan, reflecting an increase of 2.19%, and the stock has cumulatively risen by 1.29% since the concentration of shares began [2] - The margin trading data shows that as of August 29, the total margin balance for the stock is 194 million yuan, with an increase of 8.48 million yuan, or 4.58%, since the concentration of shares began [2] Group 2 - The company's semi-annual report reveals that it achieved operating revenue of 167 million yuan in the first half of the year, a year-on-year decrease of 15.97%, and a net profit of -26.98 million yuan, a decline of 2.45% year-on-year, with basic earnings per share at -0.2274 yuan [2]

Financial Performance - The company's total revenue for the first half of 2025 was 167 million yuan, a year-on-year decrease of 15.97% [1] - The net profit attributable to the parent company was -26.98 million yuan, a decline of 2.45% year-on-year [1] - In Q2 2025, total revenue was 72.83 million yuan, down 40.64% year-on-year, with a net profit of -18.89 million yuan, a decrease of 87.31% [1] Key Financial Ratios - Gross margin was 19.48%, a decrease of 31.91% compared to the previous year [1] - Net margin was -16.01%, down 26.71% year-on-year [1] - The ratio of selling, administrative, and financial expenses to revenue was 28.08%, an increase of 14.4% year-on-year [1] Balance Sheet Highlights - Cash and cash equivalents decreased by 34.72% to 224 million yuan [1] - Accounts receivable stood at 383 million yuan, a slight decrease of 0.84% [1] - Interest-bearing liabilities increased by 5.24% to 69.08 million yuan [1] Earnings Per Share - Earnings per share remained at -0.23 yuan, a decrease of 0.31% year-on-year [1] - Operating cash flow per share was -0.12 yuan, down 45.65% compared to the previous year [1] Historical Performance Insights - The company's historical median ROIC since listing is 11.56%, with the worst year being 2023 at -8.78% [3] - The company has reported losses in three out of its years since listing, indicating a fragile business model [3] - The average operating cash flow over the past three years is only 3.22% of current liabilities, suggesting potential liquidity concerns [3]

Core Viewpoint - The company has adjusted the upper limit for its share repurchase program from 22.46 CNY per share to 43.27 CNY per share, effective from August 28, 2025, to ensure the smooth execution of the repurchase plan [1][3]. Summary by Sections Share Repurchase Overview - On January 8, 2025, the company approved a share repurchase plan using its own funds, with a total amount between 20 million CNY and 40 million CNY, and a price limit of 22.46 CNY per share [2]. - As of August 26, 2025, the company has repurchased 292,600 shares, accounting for 0.244% of the total share capital, with a total expenditure of approximately 4.65 million CNY [2]. Reasons for Adjustment - The adjustment in the price limit was made due to the company's stock price consistently exceeding the original upper limit, reflecting the company's value recognition [3]. - The new price limit of 43.27 CNY per share is set at 150% of the average trading price over the 30 trading days prior to the board's decision [3]. Impact of Adjustment - The adjustment complies with relevant laws and regulations, and the company believes it will not harm the interests of the company or minority shareholders [4]. - The company asserts that the adjustment will not adversely affect its normal operations, profitability, debt obligations, or future development [4].

证券代码：301228 证券简称：实朴检测 公告编号：2025-057 实朴检测技术（上海）股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》及相关公告格式规定，将实朴检测技术（上海）股份有限公司（以 下简称"公司"）2025 年半年度募集资金存放与使用情况报告如下： 一、募集资金基本情况 (一)实际募集资金金额和资金到账时间 根据中国证券监督管理委员会于 2021年12月21日核发的"证监许可[2021]4041号"文《关 于同意实朴检测技术（上海）股份有限公司首次公开发行股票注册的批复》，公司获准向社 会公开发行人民币普通股股票 3,000.00 万股，每股面值为人民币 1 元，每股发行价格人民币 20.08 元，募集资金总额为人民币 602,400,000.00 元，扣除发行费用（不含增值税）人民币 76,066,531.36 元，实际募集资金净额为人民币 526,333,468.64 ...

实朴检测技术（上海）股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：实朴检测技术（上海）股份有限公司 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上 | 上市公司核算的会 | 2025 | 年期初占用 | 2025 年半年度占用 | 2025 年半年度占用 | 2025 | 年半年度偿还 | 2025 年半年度期末 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 市公司的关 | | | | 累计发生金额（不含 | | | | | | | | | | 联关系 | 计科目 | 资金余额 | | 利息） | 资金的利息（如有） | 累计发生金额 | | 占用资金余额 | 因 | | | 控股股东、实际控 | | | | | | | | | | | | 非经营性占用 | | 制人及其附属企业 | | | | | | | | | | | | | | 小计 | - | - | - | | | | | | ...

证券代码：301228 证券简称：实朴检测 公告编号：2025-059 实朴检测技术（上海）股份有限公司 关于2025年半年度计提信用减值准备 及资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次计提减值准备的情况概述 实朴检测技术（上海）股份有限公司（以下简称"公司"）根据《企业会计 准则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 运作》《深圳证券交易所创业板上市公司自律监管指南第1号——业务办理》和 公司相关会计政策的规定，基于谨慎性原则，为真实准确地反映公司的财务、资 产和经营状况，对合并报表范围内截至2025年6月30日的各类资产进行了全面清 查，对各项资产减值的可能性进行了充分的评估和分析，判断存在可能发生减值 的迹象，确定了需计提的减值准备。 根据《深圳证劵交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第2号——创业板上市公司规范运作》等相关法律法规以及《公司章 程》的相关规定，本次计提减值准备无需提交公司董事会或股东大会审议。 二、本次计提减值准备的范围和总金额 2025年半年度 ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 证券代码：301228 证券简称：实朴检测 公告编号：2025-054 实朴检测技术（上海）股份有限公司 第二届监事会第十七次会议决议公告 实朴检测技术（上海）股份有限公司（以下简称"公司"）第二届监事会第 十七次会议于 2025 年 8 月 26 日在公司会议室以通讯方式召开。会议通知已于 2025 年 8 月 15 日通过邮件方式送达各位监事。本次会议应出席监事 3 人，实际 出席监事 3 人。本次会议由监事会主席胡佩雷先生召集并主持。本次会议的召集、 召开和表决程序符合《中华人民共和国公司法》等法律、法规和《公司章程》的 有关规定，会议合法有效。 二、监事会会议审议情况 经与会监事认真审议，形成以下决议： （一）审议通过《关于<2025 年半年度报告>及其摘要的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 （二）审议通过《关于<2025 年半年度募集资金存放与使用情况的专项报告> 的议案》 公司募集资金的存放与使用符合《上市公司募集资金监管规则》《深圳证券 交易所上市公司自 ...